Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder

Withdrawn before enrolling · Phase 2

Conditions studied: Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Diseases

In brief

The purpose of this study is to evaluate adherence to treatment with, and safety and tolerability of, the medical information device #1 (MIND1) system in subjects with Schizophrenia or Bipolar I Disorder who are currently treated with oral aripiprazole.

Key facts

Study ID

NCT01981811

Run by

Otsuka Pharmaceutical Development & Commercialization, Inc.

People needed

0

Starts

2014-03-01

Expected to finish

2014-12-01

Last updated by the study team

2015-04-28

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females 18 to 65 years of age, inclusive, at time of informed consent
• Schizophrenia: Patients with two or more exacerbations of symptoms in past year leading to an intervention, per investigator's judgment (ie, inpatient psychiatric hospitalization, psychiatric ER visit, admission to partial hospitalization program, crisis residential treatment, etc.). This does not include outpatient adjustment of medication.
• Bipolar I Disorder: Patients with at least one manic episode or exacerbation of bipolar symptoms in past year resulting in an intervention, per Investigator's judgment (i.e., inpatient psychiatric hospitalization, psychiatric ER visit, admission to partial hospitalization program, crisis residential treatment, etc.) This does not include outpatient adjustment of medication.
• Current primary Axis-1 diagnosis of bipolar 1 disorder or schizophrenia as defined by DSM-IV-TR criteria
• Bipolar 1 disorder patients with a total YMRS score of 10 to 25 (inclusive)
• Schizophrenia patients with a total PANSS score of 60 to 90 (inclusive)
• Currently prescribed oral Aripiprazole for either bipolar 1 disorder or schizophrenia. No changes in their Aripiprazole dose or regimen 2 weeks before screening.
• Subjects must be able to tolerate blood draws.
• If subject is on other psychotropic medications, he/she must be on a stable dose and regimen over the last 2 weeks.

You may not qualify if…

• Subjects with a current Axis I (DSM-IV-TR) diagnosis other than bipolar 1 disorder or schizophrenia
• Subjects with a current Axis II (DSM-IV-TR) diagnosis
• History of inpatient hospitalization for any psychiatric reason within 2 months before screening
• Subjects who reside or attend a facility where medication is administered to them
• Subject has received any investigational product within the last 30 days
• Allergic, intolerant, or unresponsive to prior treatment with Aripiprazole or other quinolinones
• History of hypersensitivity to antipsychotic agents

Where it is running

• Study site — Cerritos, California, United States
• Study site — Garden Grove, California, United States
• Study site — Long Beach, California, United States
• Study site — National City, California, United States
• Study site — Oceanside, California, United States
• Study site — San Diego, California, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Atlanta, Georgia, United States
• Study site — St Louis, Missouri, United States
• Study site — Marlton, New Jersey, United States
• Study site — Dayton, Ohio, United States
• Study site — Irving, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.